D Rjosk
Overview
Explore the profile of D Rjosk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schindlbeck C, Hantschmann P, Zerzer M, Jahns B, Rjosk D, Janni W, et al.
Int J Gynecol Cancer
. 2007 Apr;
17(5):1047-55.
PMID: 17433065
Examination of tumor biological factors for prognostic and predictive indicators is not part of routine testing in ovarian cancer. As in other tumors, the detection of hematogenous tumor spread could...
2.
Schindlbeck C, Janni W, Shabani N, Kornmeier A, Rack B, Rjosk D, et al.
J Cancer Res Clin Oncol
. 2005 May;
131(8):539-46.
PMID: 15887027
Purpose: The presence of isolated tumor cells in the bone marrow (ITC-BM) is an independent prognostic factor in all stages of breast cancer. Both the expression/amplification of human epithelial growth...
3.
Janni W, Rjosk D, Strobl B, Bergauer F, Linka F, Dimpfl T, et al.
Gynakol Geburtshilfliche Rundsch
. 2002 Mar;
41(3):166-73.
PMID: 11904473
Introduction And Objective: A clinically important myelosuppression due to adjuvant chemotherapy is seen more frequently as dosage is intensified and new drugs are used. The assessment of the cytopenia expected...
4.
Janni W, Rjosk D, Braun S
Clin Breast Cancer
. 2002 Mar;
1(3):217-25.
PMID: 11899646
Data are emerging about the prognostic relevance of occult metastatic cells in the bone marrow of patients with various solid tumors. Discrepancies among different studies on the prognostic relevance of...
5.
Janni W, Strobl B, Rack B, Rjosk D, Schindlbeck C, Hantschmann P, et al.
Dtsch Med Wochenschr
. 2002 Jan;
127(3):71-7.
PMID: 11797143
Background And Objective: In the last few years special attention has been paid to the serum concentration of haemoglobin in patients with cancer. It was the aim of this study...
6.
Janni W, Shabani N, Dimpfl T, Starflinger I, Rjosk D, Peschers U, et al.
J Cancer Res Clin Oncol
. 2001 Jul;
127(7):455-62.
PMID: 11469684
Background: Local recurrence remains a major concern after primary treatment of breast cancer and has a major impact on subsequent survival. While most studies report a poorer survival rate in...
7.
Janni W, Rjosk D, Dimpfl T, Haertl K, Strobl B, Hepp F, et al.
Ann Surg Oncol
. 2001 Jul;
8(6):542-8.
PMID: 11456055
Background: Breast-conserving therapy has been demonstrated to be just as safe and a less disruptive experience compared with mastectomy for surgically manageable breast cancer. There is, however, no agreement in...
8.
Janni W, Hepp F, Rjosk D, Kentenich C, Strobl B, Schindlbeck C, et al.
Cancer
. 2001 Jul;
92(1):46-53.
PMID: 11443608
Background: The current study examines the fate of occult metastatic cells detected in bone marrow (BM) at primary diagnosis and evaluates whether persistently positive findings support the prognostic influence of...
9.
Braun S, Cevatli B, Assemi C, Janni W, Kentenich C, Schindlbeck C, et al.
J Clin Oncol
. 2001 Mar;
19(5):1468-75.
PMID: 11230493
Purpose: In node-negative patients, of whom up to 30% will recur within 5 years after diagnosis, markers are still needed that identify patients at high enough risk to warrant further...
10.
Janni W, Bergauer F, Rjosk D, Lohscheidt K, Hagena F
Zentralbl Chir
. 2001 Mar;
126(1):32-8.
PMID: 11227291
Introduction: In several studies, low-molecular-weight-heparins (LMWH) have been shown to be as effective in the prevention of deep vein thrombosis (DVT) as unfractionated heparin. However, different LMWHs vary significantly in...